Advertisement
Canada markets closed
  • S&P/TSX

    21,708.44
    +52.39 (+0.24%)
     
  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     
  • DOW

    37,775.38
    +22.07 (+0.06%)
     
  • CAD/USD

    0.7255
    -0.0008 (-0.12%)
     
  • CRUDE OIL

    85.71
    +2.98 (+3.60%)
     
  • Bitcoin CAD

    84,706.59
    -845.94 (-0.99%)
     
  • CMC Crypto 200

    1,250.42
    +364.89 (+38.55%)
     
  • GOLD FUTURES

    2,415.60
    +17.60 (+0.73%)
     
  • RUSSELL 2000

    1,942.96
    -4.99 (-0.26%)
     
  • 10-Yr Bond

    4.6470
    +0.0620 (+1.35%)
     
  • NASDAQ futures

    17,282.00
    -265.25 (-1.51%)
     
  • VOLATILITY

    18.00
    -0.21 (-1.15%)
     
  • FTSE

    7,877.05
    +29.06 (+0.37%)
     
  • NIKKEI 225

    36,818.81
    -1,260.89 (-3.31%)
     
  • CAD/EUR

    0.6825
    +0.0004 (+0.06%)
     

Stocks in play: BioVaxys Technology Corp.

Announced today that it has filed with the United States Patent & Trademark Office a provisional patent application for its haptenized viral antigen vaccine platform to elicit a broad cross-reactive immune response against most or all sarbecoviruses, the family of Coronaviruses that includes SARS-CoV-2, which causes Covid-19. BioVaxys Technology Corp. shares C.BIOV are trading unchanged at $0.35.

Read: